Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII

Sam Schulman, Geir E. Tjønnfjord, Richard Wallensten, Uri Martinowitz, Gili Kenet

Research output: Contribution to journalArticlepeer-review

Abstract

The administration of recombinant activated factor VII (rFVIIa) by continuous infusion has provided a safe and convenient alternative to bolus injections in haemophiliacs with inhibitors, but it has only been reported in a single case with congenital factor VII (FVII) deficiency. The results of 12 consecutive surgical procedures in 7 patients with congenital FVII deficiency are reported here. rFVIIa was always given in continuous infusion, aiming at plasma FVII activity of 0.5 IU/mL. Treatment was given for 2 to 7 days with a mean total dose of 7.8 mg rFVIIa. Blood loss was as expected from the different types of procedures and the only thromboembolic complication was a superficial thrombophlebitis at the infusion site. This mode of substitution was therefore safe, effective and well tolerated.

Original languageEnglish
Pages (from-to)1177-1180
Number of pages4
JournalThrombosis and Haemostasis
Volume94
Issue number6
DOIs
StatePublished - Dec 2005
Externally publishedYes

Keywords

  • Bleeding
  • Factor VII deficiency
  • Recombinant factor VIIa
  • Surgery

Fingerprint

Dive into the research topics of 'Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII'. Together they form a unique fingerprint.

Cite this